The integral divalent cation within the intermolecular purine*purine{middle dot}pyrimidine structure: a variable determinant of the potential for and characteristics of the triple helical association
Scott W. Blume(University of Alabama at Birmingham), Donald M. Miller(University of Louisville), Charles A. Mayfield(Baylor College of Medicine), Jacob Lebowitz(University of Alabama at Birmingham), Vincenzo Guarcello(University of Alabama at Birmingham), Paula J. Bates(University of Louisville), Wolfgang Zacharias(University of Alabama at Birmingham), John O. Trent(University of Louisville), Nadarajah Vigneswaran(University of Alabama at Birmingham), David Jones(Memorial Sloan Kettering Cancer Center), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 28
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k